CD19 and B-cell chronic lymphocytic leukemia: A phase I-II trial, sponsored by the National Cancer Institute, is currently evaluating a fully human CD19-targeting CAR T-cell (Hu19-CD828Z) in patients with CLL/SLL (NCT06364423).